Stay updated with breaking news from Thierry Lambert. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lyon, France – 29 April 2024 – 6pm CET – Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today publishes its results for the year ending 31...
Box Content Cloud validated to protect and manage confidential and sensitive health data in France
Phase III's primary endpoint will be visual acuity, with secondary endpoints including assessment of cognitive and motor functions, The FDA confirmed that this sole Phase III trial would secure
Phase III's primary endpoint will be visual acuity, with secondary endpoints including assessment of cognitive and motor functions,The FDA confirmed that this sole Phase III trial would secure Batten-1
This press release updates an earlier issuance with updated language throughout.Phase III's primary endpoint will be visual acuity, with secondary endpoints including assessment of cognitive and motor